LSE - AIM:MTPH.L

Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders

Retrieved on: 
Wednesday, January 11, 2023
News, MTP, Xbox, The Meeting, Canada Business Corporations Act, Final order, Epidermal growth factor, Meeting, Arrangement, Circular, Traffic barrier, Central nervous system, Therapy, SEDAR, Hearing, BTI, Pharmaceutical industry, Financial adviser, HAVEN

The Meeting is scheduled to be held virtually at meetnow.global/MUTHYPM on February 3, 2023 at 1:00 p.m. (Vancouver time).

Key Points: 
  • The Meeting is scheduled to be held virtually at meetnow.global/MUTHYPM on February 3, 2023 at 1:00 p.m. (Vancouver time).
  • Bioasis securityholders of record as of the close of business on December 30, 2022, are entitled to receive notice of and vote at the Meeting.
  • The Board unanimously recommends that Bioasis securityholders vote in favour of the Arrangement.
  • Bioasis securityholders are urged to read the Circular and its appendices carefully and in their entirety.

Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc

Retrieved on: 
Tuesday, December 13, 2022
Acquisition, Law of the United Kingdom, Central nervous system, Traffic barrier, TSX Venture Exchange, Arrangement, MTP, Research, Britain–India–Nepal Tripartite Agreement, BTI, Ladenburg Thalmann, Glioblastoma, Goodmans, Tripartite, LLP, Xbox, Degenerative disease, Therapy, AIM, ADSS, Exercise, Canada Business Corporations Act, Proxy, PIPE, Supreme court, SEDAR, The Meeting, Security (finance), Pharmaceutical industry, Holding company, Bank, Management, HAVEN

The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”).

Key Points: 
  • The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”).
  • We are very excited by the prospects for this transaction given the evident synergies between Bioasis and Midatech”.
  • Under the Arrangement Agreement, Midatech has agreed to advance a bridge loan in the amount of US$750,000 to Bioasis following the completion of the Registered Direct Offering (the “Midatech Bridge Loan”).
  • Bioasis’ obligations under the Midatech Bridge Loan are secured by a second-ranking pledge of all of its assets.